News Focus
News Focus
icon url

volgoat

03/31/16 8:06 PM

#260407 RE: corporalagarn #260405

The best possibility is a 1/20 or higher RS and continued dilution.

What do they care? They will just keep receiving options and their salary.

Once Bavi fails I/O, it's on to BB's....

There is no way to approval now for years, there aren't even any trials going on....

Not many options......not any data besides failed data and mice.
icon url

Protector

04/01/16 10:09 AM

#260441 RE: corporalagarn #260405

corporal, you are jumping into the wrong conclusion.

We are talking about a transition here and the list contained the so wanted 'up-front cash' deal by many posters.

In all cases the end station is that Bavituximab end up in a combo and I don't see how this screws us.